We are a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Our nanotherapeutics target cellular energy impairments that are common to many diseases.
Our nanotherapeutic platform enables the creation of clean-surfaced,
catalytically-active nanocrystals for therapeutic use. We are advancing a pipeline of these nanotherapeutics to address high unmet medical needs, starting with neurodegenerative diseases.
We believe in applying innovations to therapeutic challenges that currently have no effective solutions. With the right mix of experience, expertise, and creativity, we are changing the landscape of clinical development.
Global ALS Awareness Day, June 21st
“ALS is a debilitating disease that rapidly robs a person of the ability to move, talk, eat, and breathe. At Clene Nanomedicine, we are working very hard, literally round the clock, on an innovative treatment, CNM-Au8, that may prove to bring the world a new way to look at these diseases, through the lens of energetic, catalytic repair. As a scientist at Clene, there’s nothing I want more than to add an important treatment to the arsenal against this brutal disease.”
– Karen Ho, PhD, MSc
Head, Translational Medicine